Overview
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
Status:
Completed
Completed
Trial end date:
2021-01-15
2021-01-15
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a 52 week Phase 2b study designed to evaluate the efficacy at 16 weeks and to evaluate the safety and efficacy up to 1 year in subjects with active psoriatic arthritis.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
PfizerTreatments:
PF-06700841
Criteria
Inclusion Criteria:- Active arthritis at screening/baseline as indicated by >/= 3 tender/painful and 3
swollen joints.
- Active plaque psoriasis at screening and baseline.
Exclusion Criteria:
- Non-plaque forms of psoriasis (with exception of nail psoriasis).
- History of autoimmune rheumatic disease other than PsA; also prior history of or
current, rheumatic inflammatory disease other than PsA.